News
Merck pulls Keytruda's FDA nod for third-line stomach cancer
Merck & Co will voluntarily withdraw a US marketing approval for cancer immunotherapy blockbuster Keytruda in gastric cancer, after studies intended to confirm its efficacy in this sett
